Joana Loureiro

Senior Researcher

Research group: Supramolecular Assemblies

Academic Position:Assisntant Professor (FEUP)

Background: PhD in Chemical and Biological Engineering from the University of Porto, Portugal

Major research topics

• Functionalized nano-drug delivery systems for therapeutic applications

• Conformational studies of amyloidogenic peptides

• Design and production of lipid and polymeric nanoparticles to target the blood brain barrier

• Interaction studies of therapeutic molecules with biological membranes mimics

Selected Publications

Andrade S, Pereira MC, Loureiro JA. “Caffeic acid loaded into engineered lipid nanoparticles for Alzheimer's disease therapy”, Colloids and Surfaces B: Biointerfaces, (2023) , 225, 113270

Andrade S, Nunes D, Dabur M, Ramalho MJ, Pereira MC, Loureiro JA. “Therapeutic Potential of Natural Compounds in Neurodegenerative Diseases: Insights from Clinical Trials”. Pharmaceutics, (2023), 15 (1), 212.

Fonseca-Gomes J, Loureiro JA, Tanqueiro SR, Mouro FM, Ruivo P, Carvalho T, Sebastião AM, Diogénes MJ, Pereira MC, “In vivo bio-distribution and toxicity evaluation of polymeric and lipid-based nanoparticles: a potential approach for chronic diseases treatment”. International Journal of Nanomedicine,(2020), 15, 8609-8621.

Loureiro JA, Gomes B, Rocha S, Coelho MA Pereira MC. "Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment". Colloids and Surfaces B: Biointerfaces, (2016), 145, 8-13

Loureiro JA, Crespo R, Börner H, Martins PM, Rocha FA, Coelho MA, Pereira MC, Rocha S. Fluorinated beta-sheet breaker peptides. Journal of Materials Chemistry B, (2014) Vol. 2, Pages 2259-2264.

Selected Projects

“Nanotech-double functionalized particles to transport Nucleic Acid Mimics against Staphylococcus aureus” (FCT / 2022.05853.PTDC). Beginning: 2022. Duration 24 months. Role: Principal Investigator.

“Engineered nanoformulations for glioblastoma multiforme therapy” (M-ERA-NET3/0001/2021). Beginning: 2022. Duration 26 months. Role: Researcher.

“New therapeutic strategy and new biomarker for Alzheimer's disease based on cleavage of the BDNF receptor” (MB-37-2017). Beginning: 2018. Duration 36 months. Role: Researcher.

"NANOEFEct - Nanoparticle-Enhanced Molecular Fluorescence-endoscopy for Detection of Early-stage Colorectal Adenocarcinomas" (ERA-NET: CANCER12-FP-052). Beginning: 2014. Duration 36 months. Role: Researcher.

"Antibody-directed Liposomes for Alzheimer’s Disease" (PTDC/QUI-BIQ/118076/2010) Beginning: 2012. Duration 36 months. Role: Researcher.